Compass Pathways (NASDAQ:CMPS) Stock Price Up 8.5% – Should You Buy?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS)’s share price rose 8.5% on Thursday . The stock traded as high as $11.74 and last traded at $11.7940. Approximately 2,549,103 shares were traded during trading, a decline of 29% from the average daily volume of 3,589,368 shares. The stock had previously closed at $10.87.

Wall Street Analysts Forecast Growth

CMPS has been the topic of a number of analyst reports. Morgan Stanley lifted their target price on shares of Compass Pathways from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Maxim Group lifted their target price on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Raymond James Financial restated a “buy” rating on shares of Compass Pathways in a research note on Friday. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Finally, Royal Bank Of Canada lifted their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Compass Pathways presently has a consensus rating of “Moderate Buy” and an average target price of $20.58.

Compass Pathways Stock Performance

The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $7.63 and its two-hundred day moving average is $6.90. The company has a market cap of $1.59 billion, a PE ratio of -3.75 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. On average, equities research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Institutional Trading of Compass Pathways

Hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC lifted its stake in Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Compass Pathways in the 4th quarter worth $38,000. Parallel Advisors LLC lifted its stake in Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares in the last quarter. Advisory Services Network LLC purchased a new stake in Compass Pathways in the 3rd quarter worth $41,000. Finally, North Star Investment Management Corp. lifted its stake in Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after purchasing an additional 7,000 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.